WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 200842
Description: CVT-6883, also known as GS6201 is a selective A2B adenosine antagonist, represents a novel potential approach to treating cardiopulmonary diseases. A pre-clinical study showed that CVT-6883 significantly reduced elevated markers of inflammation, fibrosis and pulmonary injury in in vivo preclinical models.
MedKoo Cat#: 200842
Chemical Formula: C21H21F3N6O2
Exact Mass: 446.16781
Molecular Weight: 446.42
Elemental Analysis: C, 56.50; H, 4.74; F, 12.77; N, 18.83; O, 7.17
CVT-6883, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.
Synonym: CVT6883; CVT 6883; CVT-6883; GS6201; GS-6201; GS 6201;
IUPAC/Chemical Name: 3-ethyl-1-propyl-8-(1-(3-(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-1H-purine-2,6(3H,7H)-dione
InChi Key: KOYXXLLNCXWUNF-UHFFFAOYSA-N
InChi Code: InChI=1S/C21H21F3N6O2/c1-3-8-30-19(31)16-18(29(4-2)20(30)32)27-17(26-16)14-10-25-28(12-14)11-13-6-5-7-15(9-13)21(22,23)24/h5-7,9-10,12H,3-4,8,11H2,1-2H3,(H,26,27)
SMILES Code: O=C(N1CCC)N(CC)C2=C(NC(C3=CN(CC4=CC=CC(C(F)(F)F)=C4)N=C3)=N2)C1=O
The following data is based on the product molecular weight 446.42 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Ortore G, Martinelli A. A2B receptor ligands: past, present and future trends. Curr Top Med Chem. 2010;10(9):923-40. Review. PubMed PMID: 20370659.
2: Kalla RV, Zablocki J, Tabrizi MA, Baraldi PG. Recent developments in A2B adenosine receptor ligands. Handb Exp Pharmacol. 2009;(193):99-122. Review. PubMed PMID: 19639280.
3: Chen H, Yang D, Carroll SH, Eltzschig HK, Ravid K. Activation of the macrophage A2b adenosine receptor regulates tumor necrosis factor-alpha levels following vascular injury. Exp Hematol. 2009 May;37(5):533-8. PubMed PMID: 19375644.
4: Chen C, Bajpai L, Mollova N, Leung K. Sensitive and cost-effective LC-MS/MS method for quantitation of CVT-6883 in human urine using sodium dodecylbenzenesulfonate additive to eliminate adsorptive losses. J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Apr 1;877(10):943-7. Epub 2009 Feb 24. PubMed PMID: 19282253.
5: Ham J, Rees DA. The adenosine a2b receptor: its role in inflammation. Endocr Metab Immune Disord Drug Targets. 2008 Dec;8(4):244-54. Review. PubMed PMID: 19075778.
6: Kalla RV, Zablocki J. Progress in the discovery of selective, high affinity A(2B) adenosine receptor antagonists as clinical candidates. Purinergic Signal. 2009 Mar;5(1):21-9. Epub 2008 Jun 21. PubMed PMID: 18568423; PubMed Central PMCID: PMC2721775.
7: Mustafa SJ, Nadeem A, Fan M, Zhong H, Belardinelli L, Zeng D. Effect of a specific and selective A(2B) adenosine receptor antagonist on adenosine agonist AMP and allergen-induced airway responsiveness and cellular influx in a mouse model of asthma. J Pharmacol Exp Ther. 2007 Mar;320(3):1246-51. Epub 2006 Dec 11. PubMed PMID: 17159162.
8: Sun CX, Zhong H, Mohsenin A, Morschl E, Chunn JL, Molina JG, Belardinelli L, Zeng D, Blackburn MR. Role of A2B adenosine receptor signaling in adenosine-dependent pulmonary inflammation and injury. J Clin Invest. 2006 Aug;116(8):2173-2182. PubMed PMID: 16841096; PubMed Central PMCID: PMC1501110.
CVT-6883, a selective A2B adenosine antagonist, represents a novel potential approach to treating cardiopulmonary diseases. A pre-clinical study showed that CVT-6883 significantly reduced elevated markers of inflammation, fibrosis and pulmonary injury in in vivo preclinical models. An initial Phase 1 study of CVT-6883 has been completed. In this randomized, double-blind, placebo-controlled, single ascending dose study in 24 healthy volunteers, CVT-6883 was well tolerated with no serious adverse events reported. In 2007, we completed a second Phase 1 trial, an ascending, multi-dose study in 30 healthy volunteers.
On November 02, 2007, CV Therapeutics, Inc. announced that data from a randomized, single-blind, placebo-controlled, multiple ascending dose Phase 1 study of CVT-6883, a potentially first in class adenosine A2B antagonist, show that a range of doses were safe and well tolerated in 30 healthy volunteers. Read more: http://www.drugs.com/clinical_trials/data-completed-phase-1-studies-novel-adenosine-a2b-antagonist-cvt-6883-show-safety-tolerability-2535.html#ixzz0xk6RUaqu.